MEDI 1341
Alternative Names: MEDI-1341; TAK 341Latest Information Update: 09 May 2024
Price :
$50 *
At a glance
- Originator MedImmune
- Developer AstraZeneca; Takeda
- Class Antibodies; Antiparkinsonians
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple system atrophy
- Phase I Parkinson's disease
Most Recent Events
- 09 May 2024 MEDI 1341 is still in Phase-I clinical trials in Parkinson's disease in USA (IV) (AstraZeneca pipeline, May 2024)
- 31 Dec 2023 MEDI 1341 receives Orphan Drug status for Multiple system atrophy (Takeda pipeline, May 2024)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (IV, Infusion)